Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss

ACADIA PHARMACEUTICALS INC

2024-Q3 EPS reported $0.50 revenue$698,195,000

NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).
Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.
Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.
Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.
Health Canada approved DAYBUE for Rett syndrome under Priority Review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.